• KOL
    • Blood Pressure
    • Giuseppe Mancia
    • Giuseppe Mancia: Influence Statistics

      Giuseppe Mancia

      Giuseppe Mancia

      Show email address

      University of Milano-Bicocca, Milan, Italy (G.M., G.G.). | University Milano-Bicocca, Milan, Italy. | University of Milano-Bicocca, Milan, Italy. | University of Milano ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Giuseppe Mancia:Expert Impact

      Concepts for whichGiuseppe Manciahas direct influence:Blood pressure,Heart rate,Metabolic syndrome,Cardiovascular risk,Hypertensive patients,Ventricular hypertrophy,Antihypertensive treatment,Heart failure.

      Giuseppe Mancia:KOL impact

      Concepts related to the work of other authors for whichfor which Giuseppe Mancia has influence:Blood pressure,Cardiovascular disease,Heart rate,Type 2 diabetes,Metabolic syndrome,Hypertensive patients,Arterial stiffness.

      KOL Resume for Giuseppe Mancia

      Year
      2022

      University of Milano-Bicocca, Milan, Italy (G.M., G.G.).

      Università Milano-Bicocca, Milan and Policlinico di Monza, Monza, Italy

      2021

      University of Milano-Bicocca (Emeritus Professor), Milan, Italy.

      Department of Medicine and Surgery.

      Wing Tech Inc., Menlo Park, CA, USA

      Policlinico di Monza, Monza, Italy

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Giuseppe Mancia is among the top experts in the world.
      Concept World rank
      lvh height27 #1
      hypertension centres #1
      diving cbf #1
      normotensive athletes #1
      24 average #1
      bpoffice addition #1
      pressioni #1
      regular sodium intake #1
      data hypertensive patients #1
      lvh definitions #1
      exercise3 #1
      italian essential hypertensives #1
      pressure greater #1
      hypertension clinic visit #1
      n3157 #1
      individuals hgi #1
      neck chamber technique #1
      hypertensive patients gls #1
      hydrochlorothiazide groups #1
      sympathetic neural overdrive #1
      24h period #1
      patients baroreflex #1
      98±48 #1
      office elevation #1
      sinoaortic afferents #1
      daytime values #1
      degree baroreflex impairment #1
      chfh #1
      case plasma norepinephrine #1
      oxford technique #1
      goal hypertension treatment #1
      topic antihypertensive #1
      baroreflexheart rate control #1
      artery smoking #1
      pressure values #1
      stiffening influence #1
      chf chfh #1
      lercanidipine vascular resistance #1
      minimal fvr #1
      antagonists antihypertensive #1
      tolerability effects profile #1
      benefit korea study #1
      118±017 #1
      microneurography peroneal nerve #1
      msna norepinephrine #1
      uncontrolled ckd #1
      measurements clinic #1
      monotherapy initial regimen #1
      cardiovascular risk regression #1
      nn1574 #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Giuseppe Mancia

      KOL-Index: 23344

      BACKGROUND: Studies have challenged the appropriateness of accepted blood pressure targets. We hypothesised that different levels of low blood pressure are associated with benefit for some, but harm for other outcomes.

      METHODS: In this analysis, we assessed the previously reported outcome data from high-risk patients aged 55 years or older with a history of cardiovascular disease, 70% of whom had hypertension, from the ONTARGET and TRANSCEND trials investigating ramipril, telmisartan, ...

      Known for Cardiovascular Outcomes | Blood Pressure | Myocardial Infarction | Sbp Mm Hg | Transcend Trials
      KOL-Index: 18434

      BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown.

      METHODS AND RESULTS: In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), patients at high vascular risk and tolerant of ACE inhibitors were randomly assigned to ramipril, telmisartan, or their combination (n=23 165). ...

      Known for Vascular Risk | Ongoing Telmisartan | Ace Intolerant Subjects | Ventricular Hypertrophy Lvh | Ramipril Global
      KOL-Index: 17895

      BACKGROUND: Blood pressure is an important determinant of the risks of macrovascular and microvascular complications of type 2 diabetes, and guidelines recommend intensive lowering of blood pressure for diabetic patients with hypertension. We assessed the effects of the routine administration of an angiotensin converting enzyme (ACE) inhibitor-diuretic combination on serious vascular events in patients with diabetes, irrespective of initial blood pressure levels or the use of other blood ...

      Known for Fixed Combination | Type 2 Diabetes | Microvascular Outcomes | Blood Pressure | Randomised Controlled Trial
      KOL-Index: 17588

      Aims: Current guidelines of hypertensive management recommend upper limits for systolic (SBP) and diastolic blood pressure (DBP). J-curve associations of BP with risk exist for some outcomes suggesting that lower limits of DBP goals may also apply. We examined the association between mean attained DBP and cardiovascular (CV) outcomes in patients who achieved an on-treatment SBP in the range of 120 to <140 mmHg in the Ongoing Telmisartan Alone and in Combination with Ramipril Global ...

      Known for Cardiovascular Outcomes | Pulse Pressure | 140 Mmhg | Heart Failure | Patients Risk
      KOL-Index: 17154

      OBJECTIVES: To compare the effects of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors on the risk of myocardial infarction, stroke, cardiovascular mortality and total mortality.

      METHODS: We conducted a meta-analysis of randomized comparative trials between angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors. Inclusion criteria were publication in peer-reviewed journals indexed in Medline, randomized comparison of angiotensin II ...

      Known for Myocardial Infarction | Enzyme Inhibitors | Receptor Blockers | Risk Stroke | Angiotensin Converting
      KOL-Index: 16996

      CONTEXT: Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials.

      OBJECTIVE: To compare mortality and morbidity outcomes in patients with hypertension and CAD treated with a calcium antagonist strategy (CAS) or a non-calcium antagonist strategy (NCAS).

      DESIGN, SETTING, AND PARTICIPANTS: Randomized, open label, ...

      Known for Calcium Antagonist | Hypertension Treatment | Coronary Artery Disease | Trandolapril Patients | Randomized Controlled Trial
      KOL-Index: 15654

      BACKGROUND: In cross-sectional studies, ambulatory blood pressure (ABP) correlates more closely than clinic BP with the organ damage of hypertension. Whether ABP predicts development or regression of organ damage over time better than clinic BP, however, is unknown.

      METHODS AND RESULTS: In 206 essential hypertensive subjects with left ventricular hypertrophy (LVH), we measured clinic supine BP, 24-hour ABP, and left ventricular mass index (LVMI, echocardiography) before and after 12 ...

      Known for Clinic Blood | Ambulatory Monitoring | Ventricular Hypertrophy | Sample Study | Lvh Regression
      KOL-Index: 15653

      BACKGROUND: The primary objective of this study was to compare the change from baseline in mean diastolic ambulatory blood pressure (ABP) at 24 h post dose (trough measurement) after 8 weeks of treatment with irbesartan or valsartan in subjects with mild-to-moderate hypertension. Secondary objectives included comparing the mean changes from baseline in systolic ABP at trough; 24-h ABP; morning and night-time ABP; self-measured systolic blood pressure (SBP) and diastolic blood pressure ...

      Known for Blood Pressure | Irbesartan Valsartan | Sbp Dbp | Greater Reductions | Antihypertensive Efficacy
      KOL-Index: 15467

      This study investigates age-related shifts in the relative importance of systolic (SBP) and diastolic (DBP) blood pressures as predictors of stroke and whether these relations are influenced by other cardiovascular risk factors. Using 34 European cohorts from the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project with baseline between 1982 and 1997, 68 551 subjects aged 19 to 78 years, without cardiovascular disease and not receiving antihypertensive treatment, were ...

      Known for Stroke Risk | Dbp Age | Mm Hg | Diastolic Blood | Europe Female Humans
      KOL-Index: 15184

      CONTEXT: The clinical use of ambulatory blood pressure (BP) monitoring requires further validation in prospective outcome studies.

      OBJECTIVE: To compare the prognostic significance of conventional and ambulatory BP measurement in older patients with isolated systolic hypertension.

      DESIGN: Substudy to the double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial, started in October 1988 with follow up to February 1999. The conventional BP at randomization was the ...

      Known for Cardiovascular Risk | Systolic Hypertension | Ambulatory Blood | Mm Hg | Topic Reproducibility
      KOL-Index: 14886

      BACKGROUND: Guidelines on hypertension regard combinations between two antihypertensive drugs to be the most important treatment strategy. Because of the complementary mechanism of action and the evidence of cardiovascular protective effects they include the combination of a calcium antagonist and an angiotensin receptor antagonist among the priorital ones to employ.

      AIMS: To determine in hypertensive patients at high cardiovascular risk whether combining Nifedipine GITS at low dose and ...

      Known for Nifedipine Gits | Cardiovascular Risk | Telmisartan Combination | Blood Pressure | Patients Monotherapy
      KOL-Index: 14765

      Aims: Blood pressure variability is associated with increased risk of cardiovascular events, particularly in high-risk patients. We assessed if variability was associated with increased risk of cardiovascular events and death in hypertensive patients at different risk levels.

      Methods and results: The Valsartan Antihypertensive Long-term Use Evaluation trial was a randomized controlled trial of valsartan vs. amlodipine in patients with hypertension and different risks of cardiovascular ...

      Known for Cardiovascular Events | Blood Pressure Variability | Patients Hypertension | Risk Death | 6 Months
      KOL-Index: 14551

      BACKGROUND: In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain.

      METHODS: We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus other drugs as required to achieve a glycated hemoglobin value of 6.5% or less. Primary end points were composites of major macrovascular events (death from ...

      Known for Vascular Outcomes | Glucose Control | Hazard Ratio 95 | Intensive Blood | Type 2
      KOL-Index: 14270

      Aims/hypothesisThe relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the ...

      Known for Cognitive Function | Cardiovascular Disease | Type 2 Diabetes | Hypoglycaemia Patients | Risk Severe

      Key People For Blood Pressure

      Top KOLs in the world
      #1
      Giuseppe Mancia
      blood pressure heart rate metabolic syndrome
      #2
      Suzanne Oparil
      blood pressure resistant hypertension cardiovascular disease
      #3
      Gianfranco Gianfranco
      blood pressure heart failure european society
      #4
      Alberto Zanchetti
      blood pressure hypertensive patients essential hypertension
      #5
      Jackson T Wright
      blood pressure african americans kidney disease
      #6
      Jan Albert Staessen
      blood pressure systolic hypertension renal denervation

      University of Milano-Bicocca, Milan, Italy (G.M., G.G.). | University Milano-Bicocca, Milan, Italy. | University of Milano-Bicocca, Milan, Italy. | University of Milano Bicocca, Monza, ITALY | University of Milano-Bicocca, Istituto Clinico Universita

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.